Baseline risk as predictor of treatment benefit: Three clinical meta-re-analyses

Statistics in Medicine

Volumn 19, Issue 24, 2000, Pages 3497-3518

  Arends, Lidia R ^a   Hoes, Arno W ^b   Lubsen, Jacobus ^c   Grobbee, Diederik E ^b   Stijnen, Theo ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c SOCAR RESEARCH SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PREMATURITY; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL PARAMETERS; TOCOLYSIS;

BAYES THEOREM; CASE-CONTROL STUDIES; CLINICAL TRIALS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; META-ANALYSIS; MODELS, STATISTICAL; PREGNANCY; REGRESSION ANALYSIS; RISK; TOCOLYSIS;

EID: 0034736556     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0258(20001230)19:24<3497::AID-SIM830>3.0.CO;2-H     Document Type: Conference Paper

References (30)

1. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials
2. Why sources of heterogeneity in meta-analysis should be investigated
3. Meta-analysis in clinical trials
4. The population risk as an explanatory variable in research syntheses of clinical trials
5. Bayesian approaches to random-effects meta-analysis: A comparative study
6. Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension
7. Cholesterol lowering and mortality: The importance of considering initial level of risk
8. Advantages and limitations of meta-analytic regressions of clinical trials data
9. Can overall results of clinical trials be applied to all patients?
10. An effect model for the assessment of drug benefit: Example of antiarrhythmic drugs in postmyocardial infarction patients
11. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts
12. Should magnesium be given for acute myocardial infarction?
13. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials
14. Risks and benefits of treating mild hypertension: A misleading meta-analysis?
15. A logistic model for trend in 2 × 2 × K tables with applications to meta-analyses
16. The relation between treatment benefit and underlying risk in meta-analysis
17. Investigating underlying risk as a source of heterogeneity in meta-analysis
18. Variation in baseline risk as an explanation of heterogeneity in meta-analysis
19. Measurement error, instrumental variables and corrections for attenuation with applications to meta-analysis
20. A bivariate approach to meta-analysis
21. Preterm labour
22. Meta-analysis and the Hippocratic principle of primum non nocere (Authors' reply)
23. Meta-analysis in clinical research
24. Blood pressure, stroke, and coronary heart disease Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
25. Some notes on baseline risk and heterogeneity in meta-analysis
26. Linear mixed models for longitudinal data
27. Investigating underlying risk as a source of heterogeneity in meta-analysis
28. Grouped random effects models for Bayesian meta-analysis